exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary needed!
 

Tiptoe can relax!

Br J Cancer. 2011 May 10. [Epub ahead of print]
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M, Laccetti P, Terrazzano G, D'Alessio G, De Lorenzo C.
Source
Dipartimento di Biologia Strutturale e Funzionale, UniversitÃ* Federico II, via Cinthia, Napoli 80126, Italy.
Abstract
Background:ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer with success, can engender cardiotoxicity and a high fraction of patients is resistant to Trastuzumab treatment.Methods:A novel human immunoRNase, called anti-ErbB2 human compact antibody-RNase (Erb-hcAb-RNase), made up of the compact anti-ErbB2 antibody Erbicin-human-compact Antibody (Erb-hcAb) and human pancreatic RNase (HP-RNase), has been designed, expressed in mammalian cell cultures and purified. The immunoRNase was then characterised as an enzymatic protein, and tested for its biological actions in vitro and in vivo on ErbB2-positive tumour cells.Results:Erb-hcAb-RNase retains the enzymatic activity of HP-RNase and specifically binds to ErbB2-positive cells with an affinity comparable with that of the parental Erb-hcAb. Moreover, this novel immunoRNase is endowed with an effective and selective antiproliferative action for ErbB2-positive tumour cells both in vitro and in vivo. Its antitumour activity is more potent than that of the parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the inhibitory growth effects, antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.Conclusion:Erb-hcAb-RNase could be a promising candidate for the immunotherapy of ErbB2-positive tumours.British Journal of Cancer advance online publication, 10 May 2011; doi:10.1038/bjc.2011.146 www.bjcancer.com.

PMID: 21559015

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Bring it on!!!!

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Wonder how soon it will be in trials?
Italy here I come!

Ellie

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

I want some of it too.

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Thanks, Lani. Found an easier-to-read abstract:

British Journal of Cancer , (10 May 2011) | doi:10.1038/bjc.2011.146
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
M Borriello, P Laccetti, G Terrazzano, G D'Alessio and C De Lorenzo

Background:

ErbB2 is an attractive target for immunotherapy, as it is a tyrosine kinase receptor overexpressed on tumour cells of different origin, with a key role in the development of malignancy. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer with success, can engender cardiotoxicity and a high fraction of patients is resistant to Trastuzumab treatment.

Methods:

A novel human immunoRNase, called anti-ErbB2 human compact antibody-RNase (Erb-hcAb-RNase), made up of the compact anti-ErbB2 antibody Erbicin-human-compact Antibody (Erb-hcAb) and human pancreatic RNase (HP-RNase), has been designed, expressed in mammalian cell cultures and purified. The immunoRNase was then characterised as an enzymatic protein, and tested for its biological actions in vitro and in vivo on ErbB2-positive tumour cells.

Results:

Erb-hcAb-RNase retains the enzymatic activity of HP-RNase and specifically binds to ErbB2-positive cells with an affinity comparable with that of the parental Erb-hcAb. Moreover, this novel immunoRNase is endowed with an effective and selective antiproliferative action for ErbB2-positive tumour cells both in vitro and in vivo. Its antitumour activity is more potent than that of the parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the inhibitory growth effects, antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.

Conclusion:

Erb-hcAb-RNase could be a promising candidate for the immunotherapy of ErbB2-positive tumours.

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Jackie and/or Lani:

Does ErbB2 mean her2+? I don't understand these acryonmyns.

thx. Kim

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Yes, Kim, they are the same thing. See the link below:

http://en.wikipedia.org/wiki/HER2/neu

And thanks for asking. I've noticed that in British publications, ErbB2 is used instead of Her2. Have always thought it's a language difference. Turned out it's more complicated than that.

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

wow Jackie - this is GREAT news.
thanks alot!

- Kim

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Great News

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Excellent news! News things on the horizon makes me confident that we WILL prevail!

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

Ok, the advantages are that there is no risk to women with mouse allergies and this also spares the hamsters. What other advantages are there. I'm not good on science.

Re: exciting new anti-her2 immunotherapy(fully-humanized,no Chinese hamster ovary nee
 

It fights the her2+ breast cancer in four different ways and is much more potent

I have a strong belief that if you weren't so afraid of trying to understand the sentences above, assuming only rocket-scientists could do so, and broke up the sentences and tried to understand a bit at a time (as if you were trying to read a foreign language) you could have figured that part out.


Its antitumour activity is more potent than that of the parental Erb-hcAb as the novel immunoconjugate has acquired RNase-based cytotoxicity in addition to the [I]inhibitory growth effects, antibody-dependent and complement-dependent cytotoxicity of Erb-hcAb.

Just like with a foreign language, you could see that the new compound has one more attribute than the three of what had been found before and that it is more potent.

You can also see that it describes herceptin as having cardiotoxicity and a substantial number of patients for whom it is not effective or becomes ineffective. That contrasts with the new construct which is selective for the cancer cells(avoiding the heart cells) and (the construct) has more mechanisms by which it works it seems.

Again, to read sentences, separate the words known from those not known (just like reading a foreign language). If some words look long and scary, substitute the words "chocolate" and/or "pecans" and or "whipped cream" them look up a few words if necessary and try to figure out what it is saying that way ie, as if it were French or Spanish or Italian.

If you add the culinary touches above, trying to read the "dry" material can be much more interesting!